Corey J. Langer, MD, director, thoracic oncology, Penn Medicine discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Moving forward with immunotherapy, Langer believes that oncologists will have answers to important ongoing questions. Who is more likely to benefit from immunotherapy? Which patients can receive immunotherapy in combination with chemotherapy and which patients should not get immunotherapy? To understand this, Langer suggest personalizing treatment and draw information from the profiles of those patients.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

IASLC World Conference on Lung Cancer

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Dr. Langer on the Future of Immunotherapy for Treatment of NSCLC